Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
- 29 June 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 22 (11) , 1568-1579
Abstract
Glioblastoma is a devastating disease with poor prognosis. Few effective chemotherapeutics are currently available, and much effort has been expended to identify new drugs capable of slowing tumor progression. The phase 0 trial design was developed to facilitate early identification of promising agents for cancer that should undergo accelerated approval. This design features an early in-human study that enrolls a small number of patients who receive subtherapeutic doses of medication with the goals of describing pharmacokinetics through drug blood level measurements and determining intratumoral concentrations of the investigational compound as well as pharmacodynamics by studying the biochemical and physiological effects of drugs. In neuro-oncology, however, the presence of the blood–brain barrier and difficulty in obtaining brain tumor tissue warrant a separate set of considerations. In this paper, we critically reviewed the protocols used in all brain tumor related in-human phase 0 and phase 0–like (“window of opportunity”) studies between 1993 and 2018, as well as ongoing clinical trials, and identified major challenges in trial design as applied to central nervous system tumors that include surgical specimen collection and storage, brain tumor drug level analysis, and confirmation of drug action. We therefore propose that phase 0 trials in neuro-oncology should include (i) only patients in whom a resection of the tumor is planned, (ii) use of clinical doses of an investigational agent, (iii) tissue sampling from enhancing and non-enhancing portions of the tumor, and (iv) assessment of drug-specific target effects. Standardization of clinical protocols for phase 0/window of opportunity studies can help accelerate the development of effective treatments for glioblastoma.Keywords
This publication has 43 references indexed in Scilit:
- Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the TreatmentClinical Cancer Research, 2009
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group StudyJournal of Clinical Oncology, 2009
- Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor ConsortiumNeuro-Oncology, 2008
- Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to PatientClinical Cancer Research, 2008
- The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical TrialsClinical Cancer Research, 2008
- Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium TrialJournal of Clinical Oncology, 2007
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Clinical Cancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug DevelopmentClinical Cancer Research, 2004